Akero Therapeutics: Efruxifermin Met Primary Endpoint for Both Dose Groups in NASH Patients

Akero Therapeutics
Akero Therapeutics (AKRO) - a clinical-stage company, today released topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3).

The study met its primary endpoint for both the 50mg . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.